
Ambrx Biopharma, Inc. (Nasdaq: AMAM), relating to its proposed sale to Johnson & Johnson. Under the terms of the agreement, AMAM shareholders will receive $28.00 in cash per share they own.
Ambrx Biopharma, Inc. (Nasdaq: AMAM), relating to its proposed sale to Johnson & Johnson. Under the terms of the agreement, AMAM shareholders will receive $28.00 in cash per share they own.